Stockscreener 앱 받기
4.38
3.55%
0.15
시간 외 거래:
4.37
-0.010
-0.23%
전일 마감가:
$4.23
열려 있는:
$4.2
하루 거래량:
404.89K
Relative Volume:
0.91
시가총액:
$269.41M
수익:
-
순이익/손실:
$-130.41M
주가수익비율:
-1.9554
EPS:
-2.24
순현금흐름:
$-67.76M
1주 성능:
-8.56%
1개월 성능:
-13.44%
6개월 성능:
-35.01%
1년 성능:
+10.05%
1일 변동 폭
$4.12
$4.395
1주일 범위
$4.12
$4.98
52주 변동 폭
$3.5001
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
GLUE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.38 | 267.88M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - MSN
Monte Rosa Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How Monte Rosa Therapeutics Inc. stock performs during market volatilityDownside Risk Evaluation and Stock Analysis - Newser
Monte Rosa Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Monte Rosa Therapeutics Reports Q2 2025 Earnings - TipRanks
Statistical indicators supporting Monte Rosa Therapeutics Inc.’s strengthDaily Pick Forecast with Entry Zones - Newser
Buy Rating for Monte Rosa Therapeutics: Promising Pipeline and Strategic Partnerships Drive Growth Potential - TipRanks
Monte Rosa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Monte Rosa (GLUE) Q2 Revenue Jumps 394% - The Globe and Mail
Monte Rosa Therapeutics reports Q2 revenue $23.194M, consensus $7.37M - TipRanks
Monte Rosa Therapeutics, Inc. SEC 10-Q Report - TradingView
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire
How institutional ownership impacts Monte Rosa Therapeutics Inc. stockEarly Entry Ideas with Momentum Potential - Newser
What are Monte Rosa Therapeutics Inc. company’s key revenue driversAchieve breakthrough gains with smart trades - Jammu Links News
Should you hold or exit Monte Rosa Therapeutics Inc. nowSector Rotation Strategy for Smart Traders - Newser
Should I hold or sell Monte Rosa Therapeutics Inc. stock in 2025Achieve breakthrough investment performance - Jammu Links News
How does Monte Rosa Therapeutics Inc. generate profit in a changing economySky-high return potential - Jammu Links News
What institutional investors are buying Monte Rosa Therapeutics Inc. stockConsistent wealth multiplication - Jammu Links News
How strong is Monte Rosa Therapeutics Inc. company’s balance sheetMaximize your portfolio’s growth potential - Jammu Links News
Does Monte Rosa Therapeutics Inc. stock perform well during market downturnsHigh-octane gains - Jammu Links News
What drives Monte Rosa Therapeutics Inc. stock priceOutstanding capital appreciation - Jammu Links News
What catalysts could drive Monte Rosa Therapeutics Inc. stock higher in 2025Unlock daily market insights for better trades - Jammu Links News
How does Monte Rosa Therapeutics Inc. compare to its industry peersFree High-Return Strategy Alerts - Jammu Links News
Options Data Show Bullish Bias in Monte Rosa Therapeutics Inc.Pattern Detection for Entry Confirmation Enabled - metal.it
Sector ETF performance correlation with Monte Rosa Therapeutics Inc.Price Movement and Market Sentiment Analysis - Newser
GLUE’s Stock Market Adventure: 19.49% YTD Growth Amidst Volatility - investchronicle.com
Will Monte Rosa Therapeutics Inc. bounce back from current supportFree Chart Breakout Buy Signal Detection - Newser
How to integrate Monte Rosa Therapeutics Inc. into portfolio analysis toolsEarnings Based Stock Performance Forecast - Newser
What makes Monte Rosa Therapeutics Inc. stock price move sharplyLow Risk High Return Opportunities Identified - metal.it
Real time scanner hits for Monte Rosa Therapeutics Inc. explainedBuy Signal System Based on Price Action - Newser
Monte Rosa Therapeutics Inc. Rebound Backed by Sentiment Shift - metal.it
Can Monte Rosa Therapeutics Inc. Regain Lost Ground This QuarterLow Risk High Return Opportunities Identified - metal.it
Monte Rosa Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveShort Term Risk Controlled Alerts - metal.it
Sector ETF performance correlation with Monte Rosa Therapeutics Inc. Daily Entry Opportunity Forecasting Tool - Newser
Monte Rosa Therapeutics Inc. Enters Reversal Setup in Weekly ChartsReal-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Real time scanner hits for Monte Rosa Therapeutics Inc. explained Chart Pattern Recognition for Profit Timing - Newser
Is Monte Rosa Therapeutics Inc. a Top Dividend Stock to Watch in 2025Consistent Win Signals - metal.it
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention Free Accurate Buy Point for Momentum Stocks - Newser
What are the technical indicators suggesting about Monte Rosa Therapeutics Inc.Consistent high-yield stocks - Jammu Links News
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):